Saniona AB (STO:SANION), a biotechnology company in the field of ion channels, announced on Monday that its collaboration partner, Cadent Therapeutics, a precision neuroscience company, has initiated phase 1 trial for CAD-1883 for the treatment of spinocerebellar ataxia (SCA) and essential tremor.
According to the company, sourced from its ion channel research platform, CAD-1883 is the first programme from its research portfolio to enter clinical development.
Saniona believes that this research platform provides potential long-term value creation in the company as these programmes enter clinical development.
CAD-1883 was discovered in a joint research programme between Saniona and Cadent Therapeutics. For patients with spinocerebellar ataxia and essential tremor, the firing pattern of neurons in the cerebellum have become dysregulated, resulting in the loss of motor control that impacts mobility and fine motor function. By changing the calcium sensitivity of small conductance calcium-activated potassium channels (SK), CAD-1883 causes potassium current to flow at lower calcium concentrations, potentially restoring neuronal firing regularity and improving motor function. Saniona is a shareholder of Cadent Therapeutics and holds the right to royalties on CAD-1883.
Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial